Serum levels of advanced glycation end products are increased in patients with type 2 diabetes and coronary heart disease
Serum levels of advanced glycation end products are increased in patients with type 2 diabetes and coronary heart disease
复制标题
DOI：
10.2337/diacare.22.9.1543
复制
发表时间：
1999-09-01
期刊：
影响因子：
16.2
通讯作者：
Hanssen, KF
中科院分区：
文献类型：
--
作者：
Kilhovd, BK;Berg, TJ;Hanssen, KF
目的 - 研究与非糖尿病对照受试者相比，2 型糖尿病患者的晚期糖基化终产物 (AGE) 和糖氧化产物 N-ε-(羧甲基)赖氨酸 (CML) 的血清水平是否升高，以及伴或不伴冠心病 (CHD) 的 2 型糖尿病患者中 AGE 和/或 CML 的水平是否存在差异。 通过免疫测定法测量了 32 名男性和 21 名女性，年龄为 59.3 +/- 6.2 岁（平均值 +/- SD），患有 2 型糖尿病 7.3 +/- 3.1 年，以及 17 名男性和 17 名女性，年龄为 56.2 +/- 4.2 岁，无糖尿病。在糖尿病患者中，有 18 名患有 CHD。 结果 - 与非糖尿病对照受试者相比，2 型糖尿病患者的 AGE 和 CML 血清水平显着升高（中位数 [第 5-95 个百分位数]：AGE 7.4 [4.4-10.9] vs. 4.2 [1.6-6.4] U/ml，P < 0.0001；CML 15.6 [5.6-29.9] 与 8.6 [4.4-25.9] U/ml，P < 0.0001）。与无 CHD 的患者相比，2 型糖尿病合并 CHD 的患者 AGE 中位水平显着升高，但 CML 水平不显着升高（8.1 [6.4-10.9] vs. 7.1 [3.5-9.8] U/ml，P = 0.03）。患者和对照受试者血清中 AGEs 和 CML 水平均呈显着正相关。 结论——与非糖尿病对照受试者相比，2 型糖尿病患者 AGEs 和 CML 水平显着升高，且 2 型糖尿病合并 CHD 患者的 AGEs 水平显着高于非糖尿病患者，但 CML 水平不显着升高。这些结果可能表明非 CML AGEs 在 2 型糖尿病患者大血管疾病的发展中发挥作用。
OBJECTIVE - To investigate whether serum levels of advanced glycation end products (AGEs) and the glycoxidation product N-epsilon-(carboxymethyl)lysine (CML) are increased in patients with type 2 diabetes compared with nondiabetic control subjects and whether levels of AGEs and/or CML differ in patients with type 2 diabetes with or without coronary heart disease (CHD).RESEARCH DESIGN AND METHODS - Serum levels of AGEs and CML were measured with an immunoassay in 32 men and 21 women aged 59.3 +/- 6.2 years (means +/- SD) with type 2 diabetes for 7.3 +/- 3.1 years and in 17 men and 17 women aged 56.2 +/- 4.2 years without diabetes. Of the patients with diabetes, 18 had CHD.RESULTS - The serum levels of AGEs and CML were significantly increased in patients with type 2 diabetes compared with nondiabetic control subjects (median [5th-95th percentile]: AGEs 7.4 [4.4-10.9] vs. 4.2 [1.6-6.4] U/ml, P < 0.0001; CML 15.6 [5.6-29.9] vs. 8.6 [4.4-25.9] U/ml, P < 0.0001). The median level of AGEs but not CML was significantly increased in patients with type 2 diabetes and CHD compared with patients without CHD (8.1 [6.4-10.9] vs. 7.1 [3.5-9.8] U/ml, P = 0.03). There were significant positive correlations between serum levels of AGEs and CML in both patients and control subjects.CONCLUSIONS - Levels of AGEs and CML were significantly increased in patients with type 2 diabetes compared with nondiabetic control subjects, and levels of AGEs but not CML were significantly higher in patients with type 2 diabetes and CHD than in patients without diabetes. These results may indicate a role for non-CML AGEs in the development of macrovascular disease in patients with type 2 diabetes.